Clover Health InvestmentsCLOV
Recorded

Clover Health Investments 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration38 minParticipants9

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Clover Health's third quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question-and-answer session. Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. Ryan, you may begin. Good afternoon, everyone.

Ryan SchmidtInvestor Relations and FP&A Manager

Joining me on our call today to discuss the company's third quarter 2026 results are Andrew Toy, Clover Health's Chief Executive Officer, and Clay Thornton, the company's Chief Financial Officer. You can find today's press release and the accompanying supplemental slides, as well as the company's most recent investor deck in the Investor Events and Presentation section of our website at investors.cloverhealth.com. This webcast is being recorded, and a replay will be available in the Investor Relations section of the Clover Health website. I would also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10-K and other SEC filings.

Ryan SchmidtInvestor Relations and FP&A Manager

Information about non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I will now turn the call over to Andrew.

Andrew ToyCEO

Thank you, Ryan, and welcome everyone to our third quarter earnings call. There is a lot to be excited about at Clover right now. We expect to deliver our first full year of GAAP net income profitability this year. Our flagship PPO continues to rank number one in the country on core HEDIS measures. Early AEP results are reinforcing the strength of our 2027 plan designs, and there is a meaningful 2027 earnings opportunity within our growing base of returning members. All of this builds on a very strong 2026 foundation.

Andrew ToyCEO

Through the first nine months, we've grown membership by nearly 50% year-over-year, increased consolidated gross profit by over $160 million, more than doubled Adjusted EBITDA to $97 million, and improved GAAP net income by nearly $100 million, which we believe positions us to be GAAP profitable on a full-year basis in 2026, an important milestone for our business. What's most important to me is what is driving our results. At Clover, we bring our health plan, clinically focused AI technology, and financial approach together in one model. Clover Assistant improves care across a broad physician network. Our full-risk structure lets us retain the entire upside value as members stay and cohorts mature, and our focused growth strategy lets us scale with discipline. We believe that is why our model is working today and getting stronger as we grow. Now, let's shift to discussing Stars.

Andrew ToyCEO

We are incredibly proud that our flagship PPO plan achieved five Stars for payment year 2028, making it the largest five-Star PPO contract in the country. Additionally, our HMO plan achieved 4.5 Stars, meaning 100% of Clover members are enrolled in plans rated at least 4.5 Stars for payment year 2028. These Star Ratings give us continued flexibility to invest in the benefits and affordable access to care that matter most to our members. Underlying this result, our HEDIS quality performance remains industry-leading. As we've explained before, this matters because CMS uses HEDIS measures to assess aspects of care quality, including preventative screenings and management of health issues such as diabetes, cancer, and heart disease. That is why we're proud that for the third year in a row, we ranked number one nationally among comparable PPO plans on core HEDIS measures.

Andrew ToyCEO

At the same time, we have not built Clover around optimizing to Stars Ratings. We are built to manage true clinical quality and total cost of care. That distinction matters. Clover Assistant empowers physicians to identify disease earlier and proactively manage chronic conditions, and our full-risk model allows us to retain the economic benefit of that care over time. The clinical impact of CA is demonstrated in our published white papers, and the financial impact can be seen in our total cost of care. These outcomes reinforce one another. Deeper CA engagement drives better clinical care and strengthens cohort economics over time. Strong Stars create more flexibility to invest in member value and support growth and retention, and our full-risk approach allows us to retain the resulting improvement in member lifetime value. We believe our 2027 plan designs reflect this compounding advantage.

Andrew ToyCEO

We approached 2027 with a disciplined product strategy centered on physician choice, access to affordable routine care, and sustainable unit economics. Our care model works best when members can engage with their physicians with minimal financial barriers. This is why our plans preserve wide network PPO choice, $0 primary care access, low specialist co-pays, broad $0 premium options, and some of the lowest Part D deductibles in our markets. We are also seeing the AEP market dynamics that we anticipated now playing out in our markets. There are planned exits, fewer PPO options, and broader benefit repricing, reinforcing the importance of our disciplined approach to plan design. While AEP remains underway, we are not providing formal 2027 guidance, but we feel good about what we are seeing so far.

Andrew ToyCEO

AEP is tracking as expected, and we believe our superior product positioning in our core markets supports another strong year of growth. With high retention and CA-powered cohort maturation, we believe 2027 will be another important step forward. This is distinctively Clover, an AI-powered model where growth, better care, and strong profitable economics compound together in Medicare Advantage. Our 2027 products are designed to extend that advantage as we scale. One of the leading indicators we watch closely is Clover Assistant coverage. The more members we reach through CA, the more opportunity we have to drive better care and stronger economics over time. Importantly, CA coverage has accelerated through the second half of 2026 and is now running ahead of last year's pace. Counterpart takes the same model beyond Clover.

Andrew ToyCEO

Our nation-leading HEDIS performance and strong financial results continue to resonate with partners as we prove out the model in third-party environments. At the same time, we are making strong progress toward our goal of serving as many people through Counterpart as we do through our growing Clover plans. Overall, we are excited about what comes next. I look forward to updating you along the way. Before I turn it over to Clay, who will walk through our third-quarter financial performance and improved guidance, I'm pleased to share that our board has appointed him Chief Financial Officer. Clay has been a terrific partner through his time as interim CFO, and I've really enjoyed working alongside him. I've greatly valued his judgment and leadership, and I look forward to continuing our partnership as we build on Clover's progress. Clay, over to you. Thank you, Andrew.

Clay ThorntonCFO

The last several months have been a great experience. I appreciate the confidence you and the board have placed in me, and I'm grateful for the opportunity to continue serving Clover in this role. I'm excited to build on the progress we've made and help bring our care model to more seniors. Now, let's turn to the third-quarter results. Andrew outlined the strategy. I'll focus on the financial results and why we see a growing earnings opportunity across 2027 and 2028. Through the first nine months of 2026, average Medicare Advantage membership grew 49% year-over-year to approximately 157,000 members. Total revenue increased 57% to approximately $2.3 billion, and consolidated gross profit grew by $161 million to $442 million. Adjusted EBITDA more than doubled to $97 million, while GAAP net income increased by $98 million to $62 million.

Clay ThorntonCFO

We are delivering this earnings growth while a substantial portion of our membership remains early in its Clover lifecycle. We are improving profitability while building a larger base of members whose economics we expect to strengthen over time. For the third quarter, total revenue was $759 million, up 53% year-over-year, and consolidated gross profit was $130 million, up 77%. Adjusted EBITDA was $16 million compared to $2 million a year ago. GAAP net income was $6 million compared to a $24 million loss in the third quarter last year. These results included approximately $11 million of other income, which partially benefited from a $4 million favorable investment valuation adjustment. The medical cost picture remains consistent with the themes we have discussed throughout the year. Inpatient utilization continues to trend favorably year-over-year across the membership.

Clay ThorntonCFO

Our year one cohort remains broadly stable, while returning cohorts are performing in line with expectations. As we have discussed previously, favorable inpatient trends can be accompanied by higher utilization in outpatient settings. That remains consistent with what we are seeing today, with outpatient utilization elevated year-over-year, but in line with our initial outlook. Our Part D performance is better than anticipated and remains a positive year-over-year contributor. Alongside our medical cost trend, our focus remains on cohort progression. Our large 2025 and 2026 join year populations are developing in line with our projections, and we are also seeing year-over-year gross profit improvement across cohorts at each stage of their Clover lifecycle. That combination is important. Continued progress in the members already under our care while we integrate a substantially larger new member population. Turning next to SG&A. Adjusted SG&A was $114 million in the quarter and $345 million year to date.

Clay ThorntonCFO

Our adjusted SG&A as a percentage of total revenues is approximately 15% year to date and has improved 120 basis points from last year. For the full year, we expect to deliver an adjusted SG&A ratio improvement at or above our original target of 100 to 150 basis points. We are realizing fixed cost leverage while continuing to invest in Clover Assistant clinical capabilities, Counterpart Health, and core insurance operations. These investments are designed to improve member economics and allow us to support a larger business more efficiently. Our balance sheet also continues to strengthen. We ended the quarter with approximately $513 million of cash equivalents, and investments, and no debt outstanding. Cash flow from operations totaled $203 million through September.

Clay ThorntonCFO

We believe that liquidity and cash generation will support our ability to self-fund expected growth, meet regulatory capital needs, and further invest in the business. Now to our full-year outlook. We are raising the low end of guidance across every metric while maintaining the high end of each range. We now expect average Medicare Advantage membership of 157,000 to 158,000 members, total revenue of $2.97 billion-$3 billion, consolidated gross profit of $540 million-$555 million, adjusted EBITDA of $75 million-$85 million, and GAAP net income of $25 million-$35 million. These narrower ranges reflect our progress through nine months and increased confidence in delivering our full-year outlook. The fourth quarter shape remains consistent with our prior outlook. Lower consolidated gross profit from normal medical cost seasonality, alongside higher SG&A as planned AEP investments increase.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day